ATLANTA—The U.S. Food and Drug Administration has accepted an investigational new drug application from Metastatix Inc. for MSX-122, which the company is developing as a treatment for various cancers and inflammatory diseases.

The IND acceptance will permit Metastatix to commence Phase I clinical studies in the U.S. to determine the safety and tolerability of MSX-122 for the treatment of solid tumors.
MSX-122 inhibits the CXCR4 receptor implicated in many cancers and inflammatory diseases. The company’s research may eventually result in a treatment to halt or prevent the metastatic spread of cancer, hence its name.

Using technology licensed from Emory University, combined with world-class expertise in medicinal chemistry, Metastatix is developing a robust portfolio of chemical compounds that block the CXCR4 receptor.

In numerous studies, these compounds have shown efficacy in validated pre-clinical models of cancer, inflammation, and T-tropic HIV infection. This groundbreaking technology was initially developed by Emory chemist, Dr. Dennis Liotta, one of the foremost experts in small-molecule drug design.
On the Web: www.metastatix.com

For TechJournal South’s profile of Metastatix, see: http://techjournalsouth.com/search/search.html

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2007, TechJournal South. All rights reserved.